King's College London

Research portal

Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies

Research output: Contribution to journalArticle

Standard

Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies. / Pavlidis, Polychronis; Komorowski, Lars; Teegen, Bianca; Liaskos, Christos; Koutsoumpas, Andreas L; Smyk, Daniel S; Perricone, Carlo; Mytilinaiou, Maria G; Stocker, Winfried; Forbes, Alastair; Bogdanos, Dimitrios P.

In: CLINICAL CHEMISTRY AND LABORATORY MEDICINE, Vol. 54, No. 2, 02.2016, p. 249-56.

Research output: Contribution to journalArticle

Harvard

Pavlidis, P, Komorowski, L, Teegen, B, Liaskos, C, Koutsoumpas, AL, Smyk, DS, Perricone, C, Mytilinaiou, MG, Stocker, W, Forbes, A & Bogdanos, DP 2016, 'Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies', CLINICAL CHEMISTRY AND LABORATORY MEDICINE, vol. 54, no. 2, pp. 249-56. https://doi.org/10.1515/cclm-2015-0376

APA

Pavlidis, P., Komorowski, L., Teegen, B., Liaskos, C., Koutsoumpas, A. L., Smyk, D. S., Perricone, C., Mytilinaiou, M. G., Stocker, W., Forbes, A., & Bogdanos, D. P. (2016). Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 54(2), 249-56. https://doi.org/10.1515/cclm-2015-0376

Vancouver

Pavlidis P, Komorowski L, Teegen B, Liaskos C, Koutsoumpas AL, Smyk DS et al. Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies. CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 2016 Feb;54(2):249-56. https://doi.org/10.1515/cclm-2015-0376

Author

Pavlidis, Polychronis ; Komorowski, Lars ; Teegen, Bianca ; Liaskos, Christos ; Koutsoumpas, Andreas L ; Smyk, Daniel S ; Perricone, Carlo ; Mytilinaiou, Maria G ; Stocker, Winfried ; Forbes, Alastair ; Bogdanos, Dimitrios P. / Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies. In: CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 2016 ; Vol. 54, No. 2. pp. 249-56.

Bibtex Download

@article{ffb235de1b704c378950debb7db6e3ae,
title = "Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies",
abstract = "BACKGROUND: Pancreatic autoantibodies (PAB) targeting GP2 and CUZD1 are Crohn's disease (CrD)-markers. The clinical significance of anti-GP2 antibodies has been assessed, but that of anti-CUZD1 remains elusive. The aim of the study was to assess the clinical utility of anti-CUZD1/anti-GP2 by novel cell-based indirect immunofluorescence (IIF) assays in CrD.METHODS: A total of 212 CrD and 249 UC patients followed up at a London IBD centre were investigated to simultaneously detect PABs, anti-GP2 and anti-CUZD1 by IIF using primate pancreatic tissue, and HEK293 over-expressing CUZD1 or GP2.RESULTS: Overall, 88 (41.5%) CrDs compared to 26 (10.4%) UCs (p<0.001) tested positive for IgA and/or IgG anti-GP2 and/or anti-CUZD1 antibodies, while ASCA were found in 67.5% CrDs versus 19.2% UCs (p<0.0001); ASCA and/or PAB (anti-GP2 or anti-CUZD1) were detected in 76% CrD versus 34% UC patients. IgG anti-GP2 antibodies were less prevalent in L2 phenotype (p=0.002) and more prevalent in patients with stricturing disease (p=0.0418), even when a higher cut-off (≥1000 RU) was used (p=0.0396). Also, anti-GP2 IgG positive CrD patients had younger age of disease onset. IgA and/or IgG ASCA and anti-GP2 IgG antibody positive CrDs had younger onset of disease (p<0.0001), were more likely to have both ileal and colonic disease (p<0.0001) and had more stricturing (p<0.0001) than seronegative patients. Clinical correlates were not found for anti-CUZD1 positivity.CONCLUSIONS: PAB testing increases ASCA's serological sensitivity for CrD. Anti-GP2 detection, in isolation or in combination with ASCA, stratify CrD patients who phenotypically are characterised by a much younger onset of disease, extensive and stricturing behaviour.",
keywords = "Adult, Antibodies, Autoantibodies, Biomarkers, Colitis, Ulcerative, Crohn Disease, Female, HEK293 Cells, Humans, Immunoglobulin A, Immunoglobulin G, Male, Membrane Glycoproteins, Membrane Proteins, Middle Aged, Phenotype, Recombinant Proteins, Saccharomyces cerevisiae",
author = "Polychronis Pavlidis and Lars Komorowski and Bianca Teegen and Christos Liaskos and Koutsoumpas, {Andreas L} and Smyk, {Daniel S} and Carlo Perricone and Mytilinaiou, {Maria G} and Winfried Stocker and Alastair Forbes and Bogdanos, {Dimitrios P}",
year = "2016",
month = feb,
doi = "10.1515/cclm-2015-0376",
language = "English",
volume = "54",
pages = "249--56",
journal = "CLINICAL CHEMISTRY AND LABORATORY MEDICINE",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH",
number = "2",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies

AU - Pavlidis, Polychronis

AU - Komorowski, Lars

AU - Teegen, Bianca

AU - Liaskos, Christos

AU - Koutsoumpas, Andreas L

AU - Smyk, Daniel S

AU - Perricone, Carlo

AU - Mytilinaiou, Maria G

AU - Stocker, Winfried

AU - Forbes, Alastair

AU - Bogdanos, Dimitrios P

PY - 2016/2

Y1 - 2016/2

N2 - BACKGROUND: Pancreatic autoantibodies (PAB) targeting GP2 and CUZD1 are Crohn's disease (CrD)-markers. The clinical significance of anti-GP2 antibodies has been assessed, but that of anti-CUZD1 remains elusive. The aim of the study was to assess the clinical utility of anti-CUZD1/anti-GP2 by novel cell-based indirect immunofluorescence (IIF) assays in CrD.METHODS: A total of 212 CrD and 249 UC patients followed up at a London IBD centre were investigated to simultaneously detect PABs, anti-GP2 and anti-CUZD1 by IIF using primate pancreatic tissue, and HEK293 over-expressing CUZD1 or GP2.RESULTS: Overall, 88 (41.5%) CrDs compared to 26 (10.4%) UCs (p<0.001) tested positive for IgA and/or IgG anti-GP2 and/or anti-CUZD1 antibodies, while ASCA were found in 67.5% CrDs versus 19.2% UCs (p<0.0001); ASCA and/or PAB (anti-GP2 or anti-CUZD1) were detected in 76% CrD versus 34% UC patients. IgG anti-GP2 antibodies were less prevalent in L2 phenotype (p=0.002) and more prevalent in patients with stricturing disease (p=0.0418), even when a higher cut-off (≥1000 RU) was used (p=0.0396). Also, anti-GP2 IgG positive CrD patients had younger age of disease onset. IgA and/or IgG ASCA and anti-GP2 IgG antibody positive CrDs had younger onset of disease (p<0.0001), were more likely to have both ileal and colonic disease (p<0.0001) and had more stricturing (p<0.0001) than seronegative patients. Clinical correlates were not found for anti-CUZD1 positivity.CONCLUSIONS: PAB testing increases ASCA's serological sensitivity for CrD. Anti-GP2 detection, in isolation or in combination with ASCA, stratify CrD patients who phenotypically are characterised by a much younger onset of disease, extensive and stricturing behaviour.

AB - BACKGROUND: Pancreatic autoantibodies (PAB) targeting GP2 and CUZD1 are Crohn's disease (CrD)-markers. The clinical significance of anti-GP2 antibodies has been assessed, but that of anti-CUZD1 remains elusive. The aim of the study was to assess the clinical utility of anti-CUZD1/anti-GP2 by novel cell-based indirect immunofluorescence (IIF) assays in CrD.METHODS: A total of 212 CrD and 249 UC patients followed up at a London IBD centre were investigated to simultaneously detect PABs, anti-GP2 and anti-CUZD1 by IIF using primate pancreatic tissue, and HEK293 over-expressing CUZD1 or GP2.RESULTS: Overall, 88 (41.5%) CrDs compared to 26 (10.4%) UCs (p<0.001) tested positive for IgA and/or IgG anti-GP2 and/or anti-CUZD1 antibodies, while ASCA were found in 67.5% CrDs versus 19.2% UCs (p<0.0001); ASCA and/or PAB (anti-GP2 or anti-CUZD1) were detected in 76% CrD versus 34% UC patients. IgG anti-GP2 antibodies were less prevalent in L2 phenotype (p=0.002) and more prevalent in patients with stricturing disease (p=0.0418), even when a higher cut-off (≥1000 RU) was used (p=0.0396). Also, anti-GP2 IgG positive CrD patients had younger age of disease onset. IgA and/or IgG ASCA and anti-GP2 IgG antibody positive CrDs had younger onset of disease (p<0.0001), were more likely to have both ileal and colonic disease (p<0.0001) and had more stricturing (p<0.0001) than seronegative patients. Clinical correlates were not found for anti-CUZD1 positivity.CONCLUSIONS: PAB testing increases ASCA's serological sensitivity for CrD. Anti-GP2 detection, in isolation or in combination with ASCA, stratify CrD patients who phenotypically are characterised by a much younger onset of disease, extensive and stricturing behaviour.

KW - Adult

KW - Antibodies

KW - Autoantibodies

KW - Biomarkers

KW - Colitis, Ulcerative

KW - Crohn Disease

KW - Female

KW - HEK293 Cells

KW - Humans

KW - Immunoglobulin A

KW - Immunoglobulin G

KW - Male

KW - Membrane Glycoproteins

KW - Membrane Proteins

KW - Middle Aged

KW - Phenotype

KW - Recombinant Proteins

KW - Saccharomyces cerevisiae

UR - http://www.scopus.com/inward/record.url?scp=84955267341&partnerID=8YFLogxK

U2 - 10.1515/cclm-2015-0376

DO - 10.1515/cclm-2015-0376

M3 - Article

C2 - 26351932

AN - SCOPUS:84955267341

VL - 54

SP - 249

EP - 256

JO - CLINICAL CHEMISTRY AND LABORATORY MEDICINE

JF - CLINICAL CHEMISTRY AND LABORATORY MEDICINE

SN - 1434-6621

IS - 2

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454